These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38774416)

  • 1. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.
    Anido-Herranz U; Fernandez-Calvo O; Ruiz-Bañobre J; Martinez-Breijo S; Fernandez-Nuñez N; Nogareda-Seoane Z; Garrido-Pumar M; Casas-Nebra J; Muñiz-Garcia G; Portela-Pereira P; Gomez-Caamaño A; Perez-Fentes DA; Santome-Couto L; Lázaro M; Molina-Diaz A; Medina-Colmenero A; Vazquez-Estevez S
    Front Oncol; 2024; 14():1385466. PubMed ID: 38774416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
    Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
    Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
    Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
    Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
    Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
    Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Palliative
    Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
    J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
    Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
    Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistent prostate cancer.
    Vidal M; Cárdenas-Perilla R; Delgado A; Morón S; Londoño Blair JL; Vega I; Correa Ochoa JJ; Rojas J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):310-318. PubMed ID: 37419250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
    Ahmadzadehfar H; Rahbar K; Baum RP; Seifert R; Kessel K; Bögemann M; Kulkarni HR; Zhang J; Gerke C; Fimmers R; Kratochwil C; Rathke H; Ilhan H; Maffey-Steffan J; Sathekge M; Kabasakal L; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):113-122. PubMed ID: 32383093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
    Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V
    Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS.
    Ahmed ME; Joshi VB; Badawy M; Pagliaro LC; Karnes RJ; Lowe V; Thorpe MP; Kwon ED; Kendi AT
    Clin Genitourin Cancer; 2021 Jun; 19(3):223-229. PubMed ID: 33632570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
    Chiang PC; Chiang PH; Chen IA; Chen YT; Wang HJ; Cheng YT; Kang CH; Chen CH; Liu YY; Su YL; Chen YH; Luo HL
    Medicine (Baltimore); 2023 Feb; 102(5):e32671. PubMed ID: 36749250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
    Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
    Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
    Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
    Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
    Badrising SK; Louhanepessy RD; van der Noort V; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam MGEH; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; Haanen JB; Vegt E; Zwart W; Bergman AM;
    Int J Cancer; 2020 Aug; 147(4):1143-1151. PubMed ID: 31875956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
    George DJ; Agarwal N; Sartor O; Sternberg CN; Tombal B; Saad F; Miller K; Constantinovici N; Guo H; Reeves J; Jiao X; Sandström P; Verholen F; Higano CS; Shore N
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):306-313. PubMed ID: 35190653
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.